Get in touch with us!












      I accept conditions of use and privacy policy of this website.

    I want to receive updated information on the latest news.

    Get in touch with us!












        I accept conditions of use and privacy policy of this website.

      I want to receive updated information on the latest news.

      An Overview

      INHIBITOR OF CYCLIN-DEPENDENT KINASE (CDK) 4 AND 6

      Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy.

      Description / Use

      Properties

      Advantages

      • Polymorphic Form A (US9193732B2) confirmed.
      • GMP Production capabilities up to 500 kg/year. Workshop OEB 4 with engineering control measures.
      • Chinese manufacturer freedom to operate for this product.
      • Development samples and standards available with CoA.
      • Impurities deeply studied. Total impurities around 0.1%.
      • Purity > 98%.
      • No monograph in force. In compliance with general regulatory requirements. Stable room temperature.
      • Industrial quantities available in Q3 2025.
      • Competitive price based on market.

      Final Product Innovator Presentations

      • 200mg tablets.
      • Combined targeted therapy with another hormonal drug (aromatase inhibitors and fulvestrant).
      * Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.

      Certifications

      U.S. FOOD & DRUG Administration
      Pharmaceuticals and Medical Devices Agency - Japan
      European Medicines Agency Science Medicines Health
      World Health Organization
      National Medical Products Administration
      Quality System Strictly Following ICH Guidelines

      Our API

      Ribociclib succinate

      • Our API ribociclib succinate is manufactured in accordance with cGMP and stringent international quality standards.

      Canagliflozin

      • Our quality control follows every stage from development of analytical methods to the control of manufacturing process, enabling us to achieve rigorous and stringent results in accordance with injectables parameters, even under aseptic conditions.

      Contact Us

      For more information
      about the products.